Astrazeneca has brought a patent infringement case against Aurobindo Pharma over an ANDA filing for Onglyza’s generic version in the US. The dispute centres on the alleged infringement of Saxagliptin hydrochloride patents before their expiry.
Read more about Astrazeneca to retain Sweetness of Onglyza